Literature DB >> 18368594

Regulatory T-cell depletion does not prevent emergence of new CD25+ FOXP3+ lymphocytes after antigen stimulation in culture.

J J Melenhorst1, P Scheinberg, J Lu, D R Ambrozak, E Sosa, L Zhao, N F Hensel, B N Savani, D C Douek, D A Price, A J Barrett.   

Abstract

BACKGROUND: The removal of human regulatory T (T(reg)) cells from a cellular product prior to the induction of a T-cell response has the potential to boost the total yield of antigen (Ag)-specific CD4(+) and CD8(+) T cells.
METHODS: We examined the effect of this manipulation on the generation of human anti-cytomegalovirus (CMV) T-cell responses. Furthermore, we examined the clonotypic composition of Ag-specific CD4(+)FOXP3(+) and CD4(+)FOXP3(-) T cells.
RESULTS: We found that the immunomagnetic depletion of CD25(+) cells had an unpredictable effect on outcome, with total yields of CMV-specific T cells either increasing or decreasing after the removal of these cells. The depletion of CD25(+) cells both removed a proportion of Ag-specific T cells and failed to eliminate a substantial population of T(reg) cells. Furthermore, using a novel T-cell receptor clonotyping technique, we found that Ag recognition induces the expression of FOXP3 in a proportion of specific T cells; these FOXP3-expressing Ag-specific CD4(+) and CD8(+) T cells were no longer capable of producing inflammatory cytokines. DISCUSSION: The depletion of CD25(+) cells from the starting population has a variable effect on the total yield of Ag-specific T cells, a proportion of which invariably acquire FOXP3 expression and lose effector function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18368594     DOI: 10.1080/14653240701853536

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  6 in total

1.  Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation.

Authors:  Robert Quan Le; J Joseph Melenhorst; Minoo Battiwalla; Brenna Hill; Sarfraz Memon; Bipin N Savani; Aarthi Shenoy; Nancy F Hensel; Eleftheria K Koklanaris; Keyvan Keyvanfar; Frances T Hakim; Daniel C Douek; A John Barrett
Journal:  Blood       Date:  2011-03-18       Impact factor: 22.113

2.  Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.

Authors:  J Joseph Melenhorst; Ann M Leen; Catherine M Bollard; Máire F Quigley; David A Price; Cliona M Rooney; Malcolm K Brenner; A John Barrett; Helen E Heslop
Journal:  Blood       Date:  2010-08-13       Impact factor: 22.113

3.  Alloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cells.

Authors:  J Joseph Melenhorst; Phillip Scheinberg; Ann Williams; David R Ambrozak; Keyvan Keyvanfar; Melody Smith; J Philip McCoy; Nancy F Hensel; Daniel C Douek; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-06       Impact factor: 5.742

4.  Donor lymphocyte count and thymic activity predict lymphocyte recovery and outcomes after matched-sibling hematopoietic stem cell transplant.

Authors:  Zachariah McIver; Jan Joseph Melenhorst; Colin Wu; Andrew Grim; Sawa Ito; Irene Cho; Nancy Hensel; Minoo Battiwalla; Austin John Barrett
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

5.  The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor.

Authors:  Phillip Scheinberg; Jan J Melenhorst; Jason M Brenchley; Brenna J Hill; Nancy F Hensel; Pratip K Chattopadhyay; Mario Roederer; Louis J Picker; David A Price; A John Barrett; Daniel C Douek
Journal:  Blood       Date:  2009-09-23       Impact factor: 22.113

6.  Isolation of highly suppressive CD25+FoxP3+ T regulatory cells from G-CSF-mobilized donors with retention of cytotoxic anti-viral CTLs: application for multi-functional immunotherapy post stem cell transplantation.

Authors:  Edward R Samuel; Lorea Beloki; Katy Newton; Stephen Mackinnon; Mark W Lowdell
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.